Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Warren Swegal, MD
Articles by Warren Swegal, MD
Warren C. Swegal, MD, discusses the role of cabozantinib (Cabometyx) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).
Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.
In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
